Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Market Cap	$564.75M	P/E Ratio	N/A
52W High	$3.60	52W Low	$0.67
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	56.9%	52W Position	81.6%
Overall Score	56	Value Score	40
Quality Score	--	Technical Score	72

EPS Current Est	$-0.71	EPS Next Est	$-0.59
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$3.06	-1.61%	2.74M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$3.06	-1.6%	2.74M
3
4
5
6

GOSS

GOSS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Gossamer Bio Inc. Data in Excel

Get Gossamer Bio Inc. Data in Excel